Cormorant Asset Management RAPP Position
Active6-Fund ConvergenceCormorant Asset Management trimmed their position in Rapport Therapeutics, Inc. (RAPP) in Q4 2025, holding $91.9M worth of shares across 3,027,521 shares.
The position was first reported in Q2 2024 and has been tracked across 7 quarterly 13F filings.
RAPP is a convergence signal: 6 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for RAP-219 in 198 days (Oct 31, 2026), making the timing of Cormorant's position particularly relevant.
Short interest stands at 14.1% of float with 10.1 days to cover, indicating significant bearish positioning against Cormorant's long thesis.
About Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is based in Boston, Massachusetts.
Full company profile →Short Interest
14.1%
10.1 days to cover
Cormorant Asset Management RAPP Position History
Frequently Asked Questions
Does Cormorant Asset Management own RAPP?
Yes. As of Q4 2025, Cormorant Asset Management holds 3,027,521 shares of Rapport Therapeutics, Inc. (RAPP) valued at $91.9M. This data comes from their SEC 13F filing.
How many hedge funds own RAPP?
6 specialist biotech hedge funds currently hold RAPP, including Baker Bros. Advisors, Perceptive Advisors, Deep Track Capital and 2 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Cormorant Asset Management first buy RAPP?
Cormorant Asset Management's position in RAPP was first reported in Q2 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Cormorant Asset Management's RAPP position increasing or decreasing?
Cormorant Asset Management trimmed their RAPP position in the most recent quarter, reducing by 165,000 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
RAPPCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Cormorant Asset ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →